Zymeworks Common Company Insiders
ZYME Stock | USD 13.40 0.06 0.45% |
Zymeworks Common employs about 294 people. The company is managed by 26 executives with a total tenure of roughly 47 years, averaging almost 1.0 years of service per executive, having 11.31 employees per reported executive. Evaluation of Zymeworks Common's management performance can provide insight into the firm performance.
Ali Tehrani CEO President, Chief Executive Officer, Co-Founder, Director |
Neil Klompas President Chief Financial Officer, Executive Vice President - Business Operations |
Zymeworks |
Zymeworks Common Management Team Effectiveness
The company has return on total asset (ROA) of (0.1469) % which means that it has lost $0.1469 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2873) %, meaning that it created substantial loss on money invested by shareholders. Zymeworks Common's management efficiency ratios could be used to measure how well Zymeworks Common manages its routine affairs as well as how well it operates its assets and liabilities.Zymeworks Common Workforce Comparison
Zymeworks Common Stock is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 5,203. Zymeworks Common holds roughly 294 in number of employees claiming about 6% of equities under Health Care industry.
The company has Profit Margin (PM) of (1.83) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.14) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.14. Zymeworks Common Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zymeworks Common insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zymeworks Common's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Zymeworks Common insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Nodelman Oleg over a week ago Insider Trading | ||
Kenneth Galbraith over two weeks ago Acquisition by Kenneth Galbraith of 300000 shares of Zymeworks Common at 10.56 subject to Rule 16b-3 | ||
Platshon Scott over a month ago Insider Trading | ||
Ecor1 Capital, Llc over a month ago Acquisition by Ecor1 Capital, Llc of 19748 shares of Zymeworks Common at 13.8747 subject to Rule 16b-3 | ||
Ecor1 Capital, Llc over a month ago Acquisition by Ecor1 Capital, Llc of 121681 shares of Zymeworks Common at 13.885 subject to Rule 16b-3 | ||
Ecor1 Capital, Llc over a month ago Acquisition by Ecor1 Capital, Llc of 029 shares of Zymeworks Common at 14.0068 subject to Rule 16b-3 | ||
Ecor1 Capital, Llc over a month ago Acquisition by Ecor1 Capital, Llc of 74125 shares of Zymeworks Common at 13.3946 subject to Rule 16b-3 | ||
Kenneth Galbraith over a month ago Acquisition by Kenneth Galbraith of 192000 shares of Zymeworks Common subject to Rule 16b-3 |
Zymeworks Common Notable Stakeholders
A Zymeworks Common stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Zymeworks Common often face trade-offs trying to please all of them. Zymeworks Common's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Zymeworks Common's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Ali Tehrani | President, Chief Executive Officer, Co-Founder, Director | Profile | |
Kenneth Galbraith | Chairman of the Board, President, Chief Executive Officer | Profile | |
Christopher Astle | Chief Financial Officer, Senior Vice President | Profile | |
Neil Klompas | Chief Financial Officer, Executive Vice President - Business Operations | Profile | |
Leone MBA | EVP CFO | Profile | |
Thomas Kreudenstein | Director Engineering | Profile | |
Nina Weisser | Director Therapeutics | Profile | |
Lota Zoth | Lead Independent Director | Profile | |
Shrinal Inamdar | Director Relations | Profile | |
Daniel JD | Corporate VP | Profile | |
Jack Spinks | Associate Relations | Profile | |
Neil MD | Chief Officer | Profile | |
Mark Hollywood | Executive Operations | Profile | |
Neil Josephson | Interim Chief Medical Officer | Profile | |
Anthony Polverino | Executive Vice President - Early Development, Chief Scientific Officer | Profile | |
Paul Moore | Chief Officer | Profile | |
Diana Papove | Senior Communications | Profile | |
Jeffrey MD | Executive Officer | Profile | |
Diana Hausman | Chief Medical Officer | Profile | |
Ryan Dercho | Senior Affairs | Profile | |
Kenneth CA | CEO Chairman | Profile | |
Lindsey BSc | Vice Development | Profile | |
Josemund MBBS | Managing Pacific | Profile | |
Laura OConnor | Head Resources | Profile | |
John Fann | Senior Sciences | Profile | |
David Poon | VP Management | Profile |
About Zymeworks Common Management Performance
The success or failure of an entity such as Zymeworks Common Stock often depends on how effective the management is. Zymeworks Common management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Zymeworks management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Zymeworks management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada. Zymeworks operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 284 people.
Please note, the presentation of Zymeworks Common's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Zymeworks Common's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Zymeworks Common's management manipulating its earnings.
Zymeworks Common Workforce Analysis
Traditionally, organizations such as Zymeworks Common use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Zymeworks Common within its industry.Zymeworks Common Manpower Efficiency
Return on Zymeworks Common Manpower
Revenue Per Employee | 258.5K | |
Revenue Per Executive | 2.9M | |
Net Loss Per Employee | 403.7K | |
Net Loss Per Executive | 4.6M | |
Working Capital Per Employee | 1.2M | |
Working Capital Per Executive | 13.7M |
Complementary Tools for Zymeworks Stock analysis
When running Zymeworks Common's price analysis, check to measure Zymeworks Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zymeworks Common is operating at the current time. Most of Zymeworks Common's value examination focuses on studying past and present price action to predict the probability of Zymeworks Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zymeworks Common's price. Additionally, you may evaluate how the addition of Zymeworks Common to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Stocks Directory Find actively traded stocks across global markets |